Pharmarise Holdings (TSE:2796) Long-Term Debt: 円9,810 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:2796 Pharmarise Holdings Corp TSE:2796
46 GF Score
Price 円505.00
GF Value 円581.10
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Pharmarise Holdings Long-Term Debt?

Pharmarise Holdings TSE:2796 46 Long-Term Debt is 円9,810 Mil as of May. 2026. GuruFocus rates TSE:2796 with a GF Score™ of 46/100 and a GF Value™ of 円581.10 (Modestly Undervalued). The stock has 10 warning signs investors should review.

Pharmarise Holdings's Long-Term Debt for the quarter that ended in May. 2026 was 円9,810 Mil.

Pharmarise Holdings's quarterly Long-Term Debt declined from May. 2025 (円11,053 Mil) to Nov. 2025 (円9,869 Mil) and declined from Nov. 2025 (円9,869 Mil) to May. 2026 (円9,810 Mil).

Pharmarise Holdings's annual Long-Term Debt increased from May. 2024 (円9,654 Mil) to May. 2025 (円11,053 Mil) but then declined from May. 2025 (円11,053 Mil) to May. 2026 (円9,810 Mil).

Pharmarise Holdings  (TSE:2796) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Pharmarise Holdings Long-Term Debt Related Terms

Pharmarise Holdings Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Pharmarise Holdings's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmarise Holdings Long-Term Debt Chart

Pharmarise Holdings Annual Data
Trend May17 May18 May19 May20 May21 May22 May23 May24 May25 May26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,085.00 5,216.00 9,654.00 11,053.00 9,810.00

Pharmarise Holdings Semi-Annual Data
Nov16 May17 Nov17 May18 Nov18 May19 Nov19 May20 Nov20 May21 Nov21 May22 Nov22 May23 Nov23 May24 Nov24 May25 Nov25 May26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,654.00 11,415.00 11,053.00 9,869.00 9,810.00
TSE:2796
46GF Score
Pharmarise Holdings Corp TSE:2796
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of 円9,810 Mil mean?
Pharmarise Holdings (TSE:2796) has a Long-Term Debt of 円9,810 Mil as of May. 2026.
Is Pharmarise Holdings' Long-Term Debt too high?
Pharmarise Holdings' current Long-Term Debt is 円9,810 Mil. Overall, Pharmarise Holdings has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmarise Holdings' Long-Term Debt compare to competitors?
Pharmarise Holdings' Long-Term Debt of 円9,810 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Healthcare Providers & Services company?
A good Long-Term Debt depends on the Healthcare Providers & Services industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Pharmarise Holdings's current Long-Term Debt is 円9,810 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmarise Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmarise Holdings (TSE:2796) is currently considered Modestly Undervalued. The stock's GF Value™ is 円581.10, compared to a current price of 円505.00 — trading 13.1% below its estimated fair value. The current Long-Term Debt is 円9,810 Mil. Pharmarise Holdings' overall GF Score™ is 46/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Pharmarise Holdings (TSE:2796), the current Long-Term Debt is 円9,810 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmarise Holdings (TSE:2796) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmarise Holdings stock appears to be undervalued. The current stock price of 円505.00 is trading 13.1% below its estimated GF Value™ of 円581.10. GuruFocus considers Pharmarise Holdings to be Modestly Undervalued.

Key valuation signals for TSE:2796:

  • Long-Term Debt: 円9,810 Mil
  • GF Value™: 円581.10 vs. price of 円505.00 (13.1% below fair value)
  • GF Score™: 46/100 with 10 warning signs

No single metric tells the full story. See the TSE:2796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmarise Holdings Business Description

Address 8 Floor, Sumitomo Nakano Sakue Building, 1-38-1 Chuo, Nakano-ku, Tokyo, JPN, 164-0011
Pharmarise Holdings Corp is engaged in the operation of dispensing pharmacies, which prescribe medicines to general patients based on the prescriptions issued by medical institutions. It is also engaged in the storage and management of medical examination records of patients on behalf of the medical institution.
46GF Score

Get the complete analysis for TSE:2796

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円505.00
Price
円581.10
GF Value